Экономические аспекты производства фармацевтической субстанции гидроксиэтилкрахмала в малых промышленных масштабах

This article describes economic aspects of the technology of drug substance hydroxyethyl starch (HES) 130/0.4 production in small industrial scale. This substance is used as plasma substitute and has several advantages over other analogs (infusion solutions based on gelatin, dextran, albumin, blood plasma etc.) such as low cost, guaranteed lack of viruses, a small number of adverse effects and health complications. Developing the technology for producing this substance is of current interest, because only foreign HES and infusion solutions from foreign manufacturers are present in the Russian market today. As of 2016, the total market volume of HES-based infusion solutions was about 157 million rubles. So, its production is quite promising. The authors of this article calculated the cost of organizing this substance production in small scale (500 kg per year). The cost of equipment, reagents and organizational procedures for the first and subsequent years was calculated. As expected, the source of funding is a grant of the Foundation for Assistance to Small Innovative Enterprises, as well as private investors interested in implementing this project. The project generates a net present value of 644470 rubles, and the investments pay-back period will be a little more than one year. In addition to repayment of resources, the project will allow developing a technology for larger scales. This will enable facilitating the organization of industrial scale pharmaceutical manufacturing.